1stOncology | September 30, 2019: Rakuten Medical, a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, reported post-hoc analysis of safety, pharmacokinetic (PK), immunogenicity and exploratory biomarker data from its RM-1929 photoimmunotherapy (PIT) Phase 1 & 1/2a studies (Press release, Rakuten Medical, SEP 30, 2019, View Source [SID1234539930]). These early clinical trials evaluated the safety and anti-tumor activity of RM-1929 PIT in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
The key findings were presented during two poster presentations at the 2019 ESMO (Free ESMO Whitepaper) Congress held this week in Barcelona.
